SynthesisCancer medicine2020
The prognostic role of C-reactive protein in patients with head and neck squamous cell carcinoma: A meta-analysis.
Synthesis in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- C-reactive protein and its ratio with albumin as a marker of poor prognosis in oral cancer: a systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Pooled it
- Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis.World journal of surgical oncology · 2024Pooled it
- Prognostic role of C-reactive protein in patients with endometrial cancer: a meta-analysis.Biomarkers in medicine · 2024Pooled it
- The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- The oral microbiota in oral squamous cell carcinoma: unravelling mechanisms and clinical potential.Cancer cell international · 2026Review
- Clinical and laboratory biomarker correlates of lip, oral cavity, and pharyngeal cancer status in a large retrospective clinical database.Frontiers in oral health · 2026Article
- Real-World Outcomes of Treatment Approaches and the Impact of Systemic Inflammation Markers on Survival in Patients with Locally Advanced and Metastatic Laryngeal Cancer.Journal of clinical medicine · 2025Article
- [Development and validation of a nomogram for predicting cervical lymph node metastasis based on hematological parameters and clinicopathological characteristics in patients with laryngeal squamous cell carcinoma].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2025Article
- Blood-Based Inflammatory Markers Are Associated with Treatment Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Anti-PD-1 Therapy: CRP as a Superior Predictive Marker.International journal of molecular sciences · 2025Article
- Prognostic Value of the CALLY Index in Hypopharyngeal Cancer Treated with Definitive Chemoradiotherapy: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2025Article
- A multimodal dataset for precision oncology in head and neck cancer.Nature communications · 2025Article
- Predictive Value of the Glasgow Prognostic Score for Prognosis in Patients with Hypopharyngeal Squamous Cell Carcinoma Treated with Curative Radiotherapy.Journal of clinical medicine · 2025Article
- The Relationship Between Non-Traumatic Fat Embolism and Fat Embolism Syndrome (FES) in Patients with Cancer.Diseases (Basel, Switzerland) · 2025Article
- Analysis of preoperative serum cytokine levels in patients with oral squamous cell carcinoma.Scientific reports · 2025Article
- The Significance of C-Reactive Protein Value and Tumor Grading for Malignant Tumors: A Systematic Review.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- p16 Overexpression in Sinonasal Squamous Cell Carcinoma: Association with Human Papillomavirus and Prediction of Survival Outcomes.Journal of clinical medicine · 2023Article
- C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.Diseases (Basel, Switzerland) · 2023Review
- Higher Risk of Recurrence in Patients Treated for Head and Neck Cancer with Low BMI and Elevated Levels of C-Reactive Protein.Cancers · 2022Article
- Prognostic value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in laryngeal cancer: What should we expect from a meta-analysis?Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic role of the C-reactive protein (CRP) in head and neck squamous cell carcinoma (HNSCC) has not been well investigated. This meta-analysis aimed to evaluate the prognostic relevance of elevated CRP levels in patients with HNSCC.
methodsA relevant literature search was performed in PubMed, Web of Science, and Embase up to September 1, 2020. The pooled odds ratio and hazard ratio (HR) with 95% confidence interval (CI) were applied to evaluate the difference in overall survival (OS), progress-free survival (PFS), and cancer-specific survival (CSS) between patients with high CRP and those without. The pooled odds ratio (OR) with 95% CI were used to assess the association between CRP and clinicopathological features.
resultsA total of 17 studies, including 4449 patients, were included. Pooled results showed that an elevated CRP was associated with worse OS (HR = 1.48, 95% CI: 1.24-1.77), CSS (HR = 1.85, 95% CI: 1.38-2.46), and PFS (HR = 1.73, 95% CI: 1.38-2.17). Male patients, lymph node metastases, and higher tumor stage were related to elevated CRP level (OR = 1.67, 95% CI: 1.34-2.09; OR = 2.40, 95% CI: 1.44-3.99; OR = 1.39, 95% CI: 1.12-1.74).
conclusionOur meta-analysis demonstrated that an elevated pretreatment of CRP indicates poor prognosis in HNSCC. Therefore, CRP is an indicator of the prognosis of patients with HNSCC and can be recommended for assessing prognoses in clinical work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.